Debiopharm Research & Manufacturing News and Activities

Debiopharm Research & Manufacturing is owned by Debiopharm International.

They are in:

• Pharmaceuticals67%
• Biotechnology33%

View the org chart displaying its 11 main executives

Most searched biographies at Debiopharm Research & Manufacturing

• Cédric Sager, Chief Executive Officer
• Liem Vu Thanh, Quality Assurance Director
• Celine Anselmetti Dayer, Director of Regulatory Affairs

Create your alert
to follow the executive moves at Debiopharm Research & Manufacturing.

Debiopharm International has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Corden Pharma has announced the acquisition of AmbioPharm  (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Debiopharm Research & Manufacturing

• Press Releases - Debiopharm
• Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer - Debiopharm
• Debiopharm to unveil new pre-clinical and clinical research advances in DDR inhibition, dual payload ADCs, and AI-driven biomarkers at AACR 2026 - Debiopharm
• GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug - Debiopharm
• StudentsPool fait rayonner l’innovation patients en remportant le 10ᵉ Challenge Qualité de vie du patient et reçoit le prix de 25'000 francs - Debiopharm
• Redefining Acromegaly Care: First Patient Randomized in Debiopharm's Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment - Debiopharm
• Debiopharm Leverages Risklick's AI-Powered Solution to Improve Protocol Development Efficiency - Debiopharm
• Swiss-Based Debiopharm Seeks To Boost Innovation In Japanese Cancer Research Through The New "Ideal Japan” Program - Debiopharm
• Debiopharm Takes a Step Forward for Children with CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation - Debiopharm
• Debiopharm Forges AI-Powered Alliance with NetTargets to Pioneer Dual-Payload ADCs Against Drug-Resistant Cancers - Debiopharm
• View more press releases Close

Social media about Debiopharm Research & Manufacturing

• Debiopharm Research & Manufacturing on Wikipedia, Google News & Yahoo Finance
• Debiopharm Research & Manufacturing on LinkedIn, X (Twitter) & YouTube